Role of Tryptase Levels in Patients With Stable Coronary Artery Disease.

Launched by UNIVERSITY OF THESSALY · May 2, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a substance called tryptase in patients who have stable coronary artery disease, a condition that affects the blood vessels supplying the heart. The researchers want to see if measuring the levels of tryptase in the blood can help them understand how serious a patient's heart condition is and if it can predict future heart problems.

To participate in this study, individuals need to be between 18 and 85 years old and have specific heart symptoms, which are checked using a scoring system. They also need to have had a positive scan that shows their heart isn't getting enough blood. However, some people may not be eligible if they have had certain recent heart procedures, allergies, autoimmune diseases, or other serious health issues. If you join the trial, you can expect to have your tryptase levels measured and monitored, contributing to valuable research that could help improve heart health in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Male and female subjects aged 18 - 85 years old.
• • Clinical symptoms of angina which are classified based on the Canadian Cardiovascular Score (CCS score)
• • Positive SPECT scan for myocardial ischemia
• Exclusion Criteria:
• • Acute Coronary Syndrome 4 weeks before the coronary catheterization
• • Percutaneous Coronary Angioplasty
• • Coronary Artery Bypass Graft
• • Active symptoms of allergy (asthma, urticaria)
• • Mastocytosis
• • Hypereosinophilia
• • Autoimmune disease
• • Cancer
• • Kidney failure
• • Myelodysplastic Syndrome
• • Denial of signing informed consent